X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2025)
Historic EBT Margin for X4 Pharmaceuticals (XFOR) over the last 6 years, with Q3 2025 value amounting to 1690.93%.
- X4 Pharmaceuticals' EBT Margin rose 48592400.0% to 1690.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 278.63%, marking a year-over-year increase of 12061400.0%. This contributed to the annual value of 1428.46% for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2025, X4 Pharmaceuticals' EBT Margin is 1690.93%, which was up 48592400.0% from 1302.79% recorded in Q2 2025.
- In the past 5 years, X4 Pharmaceuticals' EBT Margin ranged from a high of 16136.94% in Q2 2024 and a low of 6550.18% during Q3 2024
- Moreover, its 4-year median value for EBT Margin was 2121.71% (2022), whereas its average is 1405.38%.
- Over the last 5 years, X4 Pharmaceuticals' EBT Margin had its largest YoY gain of 48592400bps in 2025, and its largest YoY loss of -174397300bps in 2025.
- Quarter analysis of 4 years shows X4 Pharmaceuticals' EBT Margin stood at 2542.83% in 2022, then fell by -15bps to 2165.55% in 2023, then crashed by -224bps to 2678.61% in 2024, then skyrocketed by 37bps to 1690.93% in 2025.
- Its EBT Margin was 1690.93% in Q3 2025, compared to 1302.79% in Q2 2025 and 1.1% in Q1 2025.